# BONE MINERAL DENSITY IN PROSTATE CANCER PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY

Published: 19-12-2012
Last updated: 26-04-2024

To assess whether a change in BMD as detected big DXA (gold standard) is comparable with the decline measured by the achilles method

| | |
|---|---|
| **Ethical review** | Approved WMO |
| **Status** | Recruiting |
| **Health condition type** | Bone, calcium, magnesium and phosphorus metabolism disorders |
| **Study type** | Observational invasive |

## Summary

### ID

NL-OMON37103

**Source**
ToetsingOnline

**Brief title**
BMD during ADT

### Condition

- Bone, calcium, magnesium and phosphorus metabolism disorders
- Renal and urinary tract neoplasms malignant and unspecified

**Synonym**
bone loss, osteoporosis

**Research involving**
Human

### Sponsors and support

**Primary sponsor:** Sint Franciscus Gasthuis
**Source(s) of monetary or material Support:** Abbott,grant van farmaceutische industrie

## Intervention

**Keyword:** Achilles, androgen deprivation, Bone mineral density, prostate cancer

## Outcome measures

### Primary outcome

Compare the change in BMD between the 2 modalities

### Secondary outcome

describe course of BMD of both modalities

Identify factors that influence the BMD pattern

# Study description

### Background summary

ADT can cause osteoporosis. Recognition of patients in whom a decline in BMD will occur is difficult

### Study objective

To assess whether a change in BMD as detected big DXA (gold standard) is comparable with the decline measured by the achilles method

### Study design

serial BMD measurements by achilles and DXA-scan

### Study burden and risks

see above

# Contacts

**Public**
Sint Franciscus Gasthuis

Kleiweg 500
3045PM
NL
**Scientific**
Sint Franciscus Gasthuis

Kleiweg 500
3045PM
NL

# Trial sites

## Listed location countries

Netherlands

# Eligibility criteria

**Age**
Adults (18-64 years)
Elderly (65 years and older)

## Inclusion criteria

Prostate cancer
androgen deprivation according to Bolla schedule

## Exclusion criteria

osteoporosis
treatment with bisphophonates or RANK-ligand inhibitor

# Study design

## Design

**Study type:** Observational invasive

| | |
|---|---|
| Masking: | Open (masking not used) |
| Control: | Uncontrolled |
| Primary purpose: | Diagnostic |

### Recruitment

NL

| | |
|---|---|
| Recruitment status: | Recruiting |
| Start date (anticipated): | 26-06-2013 |
| Enrollment: | 51 |
| Type: | Actual |

## Ethics review

Approved WMO

| | |
|---|---|
| Date: | 19-12-2012 |
| Application type: | First submission |
| Review commission: | TWOR: Toetsingscommissie Wetenschappelijk Onderzoek Rotterdam e.o. (Rotterdam) |

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

| Register | ID |
|---|---|
| CCMO | NL40673.101.12 |